This Top Biotech Stock Just Got a $100 Billion “Buy” Signal

Global cancer spending topped $100 billion for the first time after climbing a whopping 10% in 2014. And that’s a major “buy” signal for one of the top biotech stock picks we’ve been recommending at Money Morning . According to a report from the IMS Institute of Health, rising drug prices and increased incidence of cancer led to the 10% spike in drug spending last year. Here’s what that means for our top investment… Tags: ABBV stock , AbbVie stock , Best Biotech Stocks , biotech stock , biotech stock to buy , biotech stocks , biotech stocks to buy , NYSE: ABBV , top biotech stocks To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post This Top Biotech Stock Just Got a $100 Billion “Buy” Signal appeared first on Money Morning - We Make Investing Profitable .